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Transcriptomic signatures for diagnosing tuberculosis in 
clinical practice: a prospective, multicentre cohort study
Long T Hoang, Pooja Jain*, Timesh D Pillay*, Mica Tolosa-Wright, Umar Niazi, Yemisi Takwoingi, Alice Halliday, Luis C Berrocal-Almanza, 
Jonathan J Deeks, Peter Beverley, Onn Min Kon, Ajit Lalvani
Summary
Background Blood transcriptomic signatures for diagnosis of tuberculosis have shown promise in case-control studies, 
but none have been prospectively designed or validated in adults presenting with the full clinical spectrum of 
suspected tuberculosis, including extrapulmonary tuberculosis and common differential diagnoses that clinically 
resemble tuberculosis. We aimed to evaluate the diagnostic accuracy of transcriptomic signatures in patients 
presenting with clinically suspected tuberculosis in routine practice.
Methods The Validation of New Technologies for Diagnostic Evaluation of Tuberculosis (VANTDET) study was nested 
within a prospective, multicentre cohort study in secondary care in England (IDEA 11/H0722/8). Patients (aged 
≥16 years) suspected of having tuberculosis in the routine clinical inpatient and outpatient setting were recruited at 
ten National Health Service hospitals in England for IDEA and were included in VANTDET if they provided consent 
for genomic analysis. Patients had whole blood taken for microarray analysis to measure abundance of transcripts 
and were followed up for 6–12 months to determine final diagnoses on the basis of predefined diagnostic criteria. The 
diagnostic accuracy of six signatures derived from the cohort and three previously published transcriptomic signatures 
with potentially high diagnostic performance were assessed by calculating area under the receiver-operating 
characteristic curves (AUC-ROCs), sensitivities, and specificities.
Findings Between Nov 25, 2011, and Dec 31, 2013, 1162 participants were enrolled. 628 participants (aged ≥16 years) 
were included in the analysis, of whom 212 (34%) had culture-confirmed tuberculosis, 89 (14%) had highly probable 
tuberculosis, and 327 (52%) had tuberculosis excluded. The novel signature with highest performance for identifying 
all active tuberculosis gave an AUC-ROC of 0·87 (95% CI 0·81–0·92), sensitivity of 77% (66–87), and specificity of 
84% (74–91). The best-performing published signature gave an AUC-ROC of 0·83 (0·80–0·86), sensitivity of 78% 
(73–83), and specificity of 76% (70–80). For detecting highly probable tuberculosis, the best novel signature yielded 
results of 0·86 (0·71–0·95), 77% (56–94%), and 77% (57–95%). None of the relevant cohort-derived or previously 
published signatures achieved the WHO-defined targets of paired sensitivity and specificity for a non-sputum-based 
diagnostic test.
Interpretation In a clinically representative cohort in routine practice in a low-incidence setting, transcriptomic 
signatures did not have adequate accuracy for diagnosis of tuberculosis, including in patients with highly probable 
tuberculosis where the unmet need is greatest. These findings suggest that transcriptomic signatures have little 
clinical utility for diagnostic assessment of suspected tuberculosis.
Funding National Institute for Health Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Tuberculosis is the leading infectious cause of death 
worldwide.1 A large proportion of the 10 million new 
cases reported in 2018 were diagnosed without 
bacteriological confirmation, indicating the shortcomings 
of available diagnostic approaches.1 WHO recommends 
that new diagnostic tests for tuberculosis be low-cost, 
easy to use, non-invasive, and achieve high sensitivity and 
specificity.2 The Xpert MTB/RIF assay (Cepheid; 
Sunnyvale, CA, USA) has transformed diagnosis of 
pulmonary tuberculosis in resource-poor settings; 
however, it has poor sensitivity for culture-negative 
tuberculosis.3,4 The low sensitivity of bacteriological 
diagnostic tools probably reflects the pauci bacillary 
nature of culture-negative and extrapulmonary tuber-
culosis, which accounts for a large and growing 
proportion of tuberculosis cases in low-incidence regions. 
Moreover, invasive sampling procedures, such as 
broncho scopy and biopsy, are expensive and carry risk. 
Therefore, there is an unmet clinical need for improved 
rapid diagnostic tools for tuberculosis without invasive 
sampling, which could improve diagnosis of culture-
negative tuber culosis and extrapulmonary tuberculosis, 
for which improved diagnostic tools are needed most.5
Blood-based, host-derived immune response biomarkers 
reflect an amplified signal to the infecting bacillus, so 
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might improve diagnostic sensitivity compared with 
micro biologically based methods.2 Whole-blood trans-
criptomic signatures that provide a broad view of the 
host response to tuberculosis have shown considerable 
promise to this end—several studies in low-incidence 
and high-incidence settings have shown accurate diffe-
rentiation of tuberculosis from healthy controls, tuber-
culosis from other diseases, and tuberculosis from latent 
tuberculosis infection.6–12
These promising studies have two major drawbacks. 
First, all but one (in young children) were case-control 
studies comprising patients with confirmed tuberculosis 
and preselected healthy or non-tubercular disease controls. 
Such studies do not reflect routine clinical practice. 
Typically, suspicion of tuberculosis needs confirmation or 
exclusion in patients with a wide range of presenting 
conditions, which might mimic tuberculosis, and who 
often have con comitant latent tuberculosis infection.13–15 
Second, these studies were predominantly restricted 
to patients with culture-confirmed pulmonary tuberculosis, 
and patients with extrapulmonary tuberculosis and 
culture-negative tuberculosis were excluded. However, 
these subgroups have the greatest unmet need for an 
improved diagnostic test. Consequently, there is a pressing 
need to derive and validate novel transcriptomic signatures 
in routine clinical practice cohorts representing the full 
clinical spectrum of tuberculosis and non-tuberculosis 
differential diagnoses. Such evidence is essential for 
clinicians and health-care systems to determine whether to 
deploy this genomic approach as a diagnostic service, and 
if so, how. We aimed to address this evidence gap in a 
large multicentre prospective cohort recruited in routine 
practice designed specifically to assess novel diagnostic 
tests for tuberculosis in low-incidence settings.
Methods
Study design and participants
We embedded an analysis of transcriptomic signatures 
within a prospective cohort study in routine clinical 
practice in England (the IGRAs in Diagnostic Evaluation 
of Active TB [IDEA] study; approved by Camden and 
Islington National Research Ethics Committee, reference 
11/H0722/8), which was designed to assess the clinical 
utility of existing and second-generation interferon-γ 
release assays (IGRAs) in the diagnostic evaluation of 
tuberculosis, as previously reported.16 The present study 
(Validation of New Technologies for Diagnostic Evaluation 
of Tuberculosis [VANTDET]), funded by the National 
Institute for Health Research Efficacy, Mechanisms 
and Evaluation programme (EME 12/65/27), builds on 
the unique value of the IDEA cohort to evaluate the 
real-life performance of new technologies, including 
Research in context
Evidence before this study
Diagnosis of tuberculosis, particularly extrapulmonary and 
culture-negative tuberculosis, which account for a large and 
growing proportion of tuberculosis in low-incidence regions, 
remains a major unmet clinical need. Blood-based host-
response biomarkers, particularly genome-wide transcriptomic 
signatures, hold promise for improving diagnosis. However, 
existing signatures were derived in case-control studies 
comprised exclusively of culture-confirmed pulmonary 
tuberculosis cases and preselected controls. Their performance 
in clinical practice in patients with a full range of tuberculosis, 
including extrapulmonary and culture-negative tuberculosis, is 
unknown. We searched PubMed for articles published 
between inception and May 31, 2020, using the search terms 
“transcriptomic”, “transcriptome”, “tuberculosis”, “TB”. This 
search yielded articles describing the derivation and validation 
of 28 relevant diagnostic transcriptomic signatures. All adult 
studies were case-control design with culture-confirmed 
pulmonary tuberculosis cases and preselected healthy or other 
disease controls.
Added value of this study
To our knowledge, this is the first study to derive novel 
transcriptomic signatures for the diagnosis of tuberculosis in 
routine clinical practice in patients with the full spectrum of 
tuberculosis recruited at the point of clinical suspicion. It is also 
the largest cohort for assessment of this technology for 
tuberculosis diagnosis, making the findings reliable as well 
as generalisable to other low-incidence settings. Among 
628 participants, the best-performing cohort-derived novel 
signature for detecting all active tuberculosis gave an area 
under the receiver-operating characteristic curve of 0·87 
(95% CI 0·81–0·92), sensitivity of 77% (66–87), and specificity 
of 84% (74–91); previously published signatures were no better 
at detecting all active tuberculosis. Diagnostic performance in 
highly probable culture-negative tuberculosis, the subgroup in 
whom the unmet clinical need is greatest and transcriptomic 
signatures have not previously been assessed, was no better. 
None of the signatures achieved optimum or minimum WHO 
criteria for a diagnostic test for tuberculosis.
Implications of all the available evidence
Transcriptomic signatures have shown promise for tuberculosis 
diagnosis in numerous case-control studies and meta-analyses. 
However, their performance when applied at the point of 
diagnostic assessment in patients presenting in routine practice 
with the full clinical spectrum of suspected tuberculosis is lower 
than anticipated. The generalisable evidence presented here 
suggests that transcriptomic signatures are of little value in the 
diagnosis of suspected tuberculosis in clinical practice in 
low-incidence settings. These findings exemplify the need for 
evaluation of new diagnostic technologies in the clinically 
relevant target population at the point of initial diagnostic 
suspicion in routine practice.
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transcriptomic signatures, for the diagnosis tuberculosis 
on samples deposited in the IDEA biobank (respiratory 
infections tissue bank 07/H0712/85+5) as patients were 
enrolled.
In the IDEA study, adults initially suspected of having 
tuberculosis by local attending clinicians in inpatient and 
outpatient infectious diseases or respiratory secondary 
care services were recruited by research nurses at the 
point of diagnostic investigation at ten National Health 
Service Trust hospitals in England (appendix p 16).16 
Patients younger than 16 years and those unable to give 
informed consent were not recruited. After recruitment, 
participants were excluded from this study if they had not 
provided consent to genomic analysis.
The study was approved by the Camden and Islington 
National Research Ethics Committee. Participants 
provided written informed consent.
Procedures
After initial enrolment, blood for IGRAs and tran scriptomic 
signature derivation was sampled and data collected in case 
report forms. Blood samples were taken for transcriptomic 
signature analysis before treatment initiation, and the 
presence or absence of tuberculosis was verified according 
to stringent, predefined previously validated criteria.16,17 
35 mL of blood was collected. RNA was extracted from 
PAXGene tubes using a blood RNA kit (PreAnalytiXl; 
Hombrechtikon, Switzerland). RNA quality control was 
done using both the NanoDrop 8000 (ThermoFisher; 
Waltham, MA, USA) and the Agilent 2100 Bioanalyzer 
(Agilent; Santa Clara, CA, USA) instruments. Global trans-
criptomic profiles of the participants were characterised 
using whole-genome-wide microarray Illumina (San 
Diego, CA, USA) gene expression platforms (HT12 version 
4 bead chip). Microarray data were submitted to the Gene 
Expression Omnibus repository with accession number 
GSE144127. The detailed protocol has been published 
previously.18 Scientists who did RNA extraction and micro-
array analysis were masked to patients’ final diagnoses by 
blocking their access to the clinical database. Participants 
were excluded at this stage if their blood sample contained 
low quality or quantity of RNA, had a missing sample date, 
their RNA was not detected, or showed outlier values on 
microarray. Outlier values were defined as falling outside 
the 95% confidence ellipse on principle component 
analysis.
Participants were followed at 2 months, 6 months, and 
12 months, with data collected on investigations, test 
results, diagnoses, and response to tuberculosis treatment. 
Participants with a definitive non-tuberculosis diagnosis 
were not followed further, because they had reached a 
diagnostic endpoint. Participants lost to follow-up or who 
withdrew before 6 months and before a definitive non-
tuberculosis diagnosis was reached were excluded.
Patients were investigated and treated by respiratory or 
infectious disease physicians in routine clinical practice. 
After the 12-month study follow-up, with all clinical, 
radiological, histological, and microbiological data 
available, participants received a definitive diagnostic 
categorisation. These outcomes were determined by 
consensus across a panel of five expert respiratory and 
infectious disease clinicians acting as part of the IDEA 
study team who were masked to the results of 
transcriptomic analyses and IGRAs, as previously 
described.16 The panel used a predefined validated 
diagnostic classification,16,17 inclu ding clinical, radio-
logical, and microbiological data. Category 1, culture-
confirmed tuberculosis, was defined as the combination 
of suggestive clinical and radiological findings and 
positive microbiological culture for Mycobacterium 
tuberculosis. Category 2, highly probable tuberculosis, 
was defined as the combination of all of the following 
stringent criteria: clinical and radiological features highly 
See Online for appendix
Figure 1: Study profile
*Recruitment was extended from Aug 31, 2013 (as used and reported in Whitworth et al16), to Dec 31, 2014, to 
maximise HIV-positive tuberculosis cases to have sufficient numbers to compare the technologies being 
evaluated in HIV-positive individuals. However, by Dec 31, 2014, this strategy only delivered 20 cases of HIV-
positive tuberculosis, still fewer than the number required to meaningfully compare the subgroups. Therefore, 
25 HIV-positive participants with tuberculosis who were excluded were randomly selected from the total number 
of 126 such cases to form a balanced group relative to the 20 HIV-positive tuberculosis cases, meaning that 101 
HIV-positive participants with tuberculosis were excluded at this stage. This study included eight HIV-positive 
patients recruited during this extension period not included in Whitworth et al,16 one of whom had tuberculosis. 
†Defined as falling outside the 95% confidence ellipse on principle component analysis.
1162 patients enrolled
329 excluded
228 did not provide consent for genomic
         analysis
41 lost to follow-up
60 withdrew
833 eligible for whole-genome microarray
153 excluded
  26 samples had low RNA quantity or
         quality
101 samples were not used for microarray*
26 samples had a missing sample date
680 eligible for inclusion
662 available for clinical categorisation
212 assigned
         to category 1—
         culture-confirmed
         tuberculosis
89 assigned




       to category 3—
       clinically
       indeterminate
       and excluded
327 assigned
         to category 4—
         other diseases
18 excluded
  8 microarray failures
10 outliers†
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suggestive of tuberculosis unlikely to be caused by 
another disease, no positive microbiological culture 
available, the attending clinician decision to treat, 
appropriate response to therapy, and supportive histo-
logical evidence if available. Categories 1 and 2 combined 
are referred to as all active tuberculosis. In category 3, 
patients had a clinically indeterminate diagnosis and 
tuberculosis was neither highly probable nor reliably 
excluded.17 Patients assigned to category 4, other diseases, 
had no evidence of active tuberculosis using a 
combination of symptoms, risk factors, and negative 
bacteriology and evidence of another diagnosis if 
available.
Statistical analysis
The primary objective of this study was to derive 
transcriptomic signatures from a cohort of patients 
presenting with clinically suspected tuberculosis in 
routine clinical care and assess their performance at 
differentiating tuberculosis from its naturally occurring 
differential diagnoses. Category 3 participants were 
excluded from analyses, because they could not be 
reliably assigned tuberculosis or other diseases status. 
All others were included in the primary analysis. A 
summary of the methods used to derive novel signatures 
from the cohort is presented in the appendix (pp 1–3, 6–7).
80% of the cohort was randomly selected as a derivation 
set using the sample function in R (version 4.0.1). 
Differentially expressed transcripts between active 
tuberculosis and other diseases groups in the derivation 
set were used to find the signatures with the lowest 
classification errors using Random Forest, Leaps 
(version 3.1), and linear discriminant analysis (MASS 
R package version 7.3-53). These signatures were then 
trained in the same derivation set and tested in the 
remaining validation set containing 20% of the cohort. To 
estimate the prediction uncertainty of the model and 
report it as error bars on the receiver operating 
characteristic curves, the training and testing of the new 
signatures were repeated 1000 times using Monte Carlo 
cross-validation (resampling without replacement by use 
of the bootstrap and sample R function), which randomly 
created 1000 new 80:20 splits of the full dataset. A similar 
strategy has been used previously.6,7
To address the possibility that transcriptomic signatures 
of host response in paucibacillary culture-negative highly 
probable tuberculosis might substantially differ from 
those in culture-positive tuberculosis, we derived three 
additional signatures (4, 5, and 6) by applying the same 
method specifically to highly probable tuberculosis and a 
randomly selected equal number of cases of other 
diseases.
The secondary objective of this study was to assess 
the performance of previously published transcriptomic 
signatures in this cohort. Three criteria suggestive of high 
diagnostic performance were used to identify the most 
rigorously derived previously published transcriptomic 
signatures to apply to our cohort: published risk score 
calculable in our cohort, comparisons of tuberculosis 
against other diseases (not healthy controls), and 
derivations from a sufficient dataset (more than 
400 participants). Existing transcriptomic signatures 
published as transcript lists without coefficients (thus 
requiring retraining in their own dataset before 
application) were not useable. Conversely, training of 
previously published transcript lists in our cohort would 
create a new signature, not representing the original. 
Furthermore, retraining of a signature before use in a 
new population is not feasible in clinical practice. Three 
previously published transcriptomic signatures met 













Median (IQR) 32 (26–42) 36 (28–45) 45 (27–57) 43 (33–56)
Range 16–81 18–76 16–79 17–87
Sex
Male 149 (70%) 45 (51%) 13 (38%) 189 (58%)
Female 62 (30%) 44 (49%) 21 (62%) 138 (42%)
Ethnic origin
Asian 12 (6%) 3 (3%) 4 (12%) 12 (4%)
Black 36 (17%) 17 (19%) 8 (24%) 62 (19%)
Hispanic 1 (<1%) 0 0 (0%) 1 (<1%)
Indian subcontinent 139 (66%) 61 (69%) 11 (32%) 150 (46%)
Middle Eastern 3 (1%) 0 0 (0%) 11 (3%)
Mixed 2 (1%) 0 0 (0%) 7 (2%)
White 19 (9%) 8 (9%) 11 (32%) 83 (25%)
Unknown 0 0 0 0
Body-mass index, kg/m²
Median (IQR) 22·6 (20·2–25·4) 22·5 (20·8–25·2) 23·6 (20·5–30·5) 24·4 (21·2–27·9)
Range 15·7–48·5 14·6–42·2 12·7–45·2 14·8–47·2
Recent known 
tuberculosis contact
52 (25%) 17 (19%) 11 (32%) 70 (21%)
History of previous 
tuberculosis
8 (4%) 6 (7%) 0 41 (13%)
Comorbidities
HIV positive 9 (4%) 11 (12%) 0 25 (8%)
None 147 (69%) 59 (66%) 14 (41%) 141 (43%)
Asthma 12 (6%) 4 (4%) 4 (12%) 38 (12%)
Diabetes 12 (6%) 3 (3%) 5 (15%) 39 (12%)
Other 41 (19%) 24 (27%) 17 (50%) 138 (42%)
Symptoms
Cough 142 (67%) 47 (53%) 16 (47%) 238 (73%)
Fever 106 (50%) 40 (45%) 6 (18%) 144 (44%)
Night sweat 111 (52%) 47 (53%) 15 (44%) 152 (46%)
Weight loss 128 (60%) 46 (52%) 12 (35%) 154 (47%)
Haemoptysis 23 (11%) 8 (9%) 1 (3%) 53 (16%)
Lethargy 113 (53%) 49 (55%) 17 (50%) 168 (51%)
Other symptoms 131 (62%) 54 (61%) 21 (62%) 144 (44%)
Data are n (%), unless otherwise specified.
Table 1: Demographic and clinical characteristics of analysed participants
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whole cohort and subgroups as the novel signatures to 
derive an area under the receiver-operating characteristic 
curves (AUC-ROC), sensitivity, and specificity.
Receiver operating characteristic analysis (ROCR 
package version 1.0-11 and EasyROC web-tool) was used 
to assess the diagnostic performance of the signatures in 
classifying patients against the final assigned diagnoses: 
category 1, category 2, and category 4. Where cases were 
significantly outnumbered by other diseases controls, a 
randomly selected size-matched sample of other diseases 
controls was used in the analysis. Sensitivity and 
specificity were calculated with the Youden Index to 
equally prioritise the two, then high sensitivity or 
specificity were selected to match with WHO targets for a 
novel confirmatory test.2 Although the WHO criteria 
were designed to guide novel diagnostics for medium-to-
high-incidence settings, they can also provide a relevant 
benchmark for performance of new tests in low-incidence 
settings. To account for the small possibility that a 
proportion of the group with highly probable tuberculosis 
had been misdiagnosed by our classification system, we 
did a sensitivity analysis as described in Kaforou et al,6 
calculating diagnostic accuracies when a true prevalence 
of tuberculosis of 80%, 85%, or 90% was assumed.
The IDEA cohort size was powered to detect a 
10% differ ence in diagnostic sensitivity between the two 
commercially available IGRAs. Accounting for the paired 
nature of the data and assuming independence of errors, 
855 patients (after loss to follow-up, withdrawal, or 
exclusion because of missing or invalid index or reference 
test results) were required to detect this difference at the 
5% significance level (two-tailed) with 90% power, based 
on a predicted 40% prevalence of active tuberculosis in 
the study population. From the resulting overall IDEA 
cohort, we used every available RNA sample from all 
patients who completed follow-up and who consented to 
genomic analysis.16
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study, and the corresponding author had final 
responsibility for the decision to submit for publication.
Results
Between Nov 25, 2011, and Dec 31, 2013, 1162 patients with 
suspected tuberculosis were enrolled, and 628 (54%) were 
included in the final analysis (figure 1). Of these 628, 301 
(48%) had active tuberculosis, 212 (34%) had culture-
confirmed tubercu losis, and 89 (14%) had highly probable 
tuberculosis (76 [85%] with culture-negative tuberculosis 
and 13 [15%] with cultures not done). The remaining 
327 (52%) patients had other diseases (figure 1). As 
planned, the small subgroup of patients with clinically 
indeterminate disease was excluded from analysis, because 
tuberculosis as a cause for their symptoms could neither 
be ruled in nor ruled out (n=34). Demographic and clinical 
characteristics of the cohort are summarised in table 1.
Of the 301 patients with active tuberculosis, 50 (17%) 
were sputum smear-positive, 101 (34%) had pulmonary 
tuberculosis, 164 (54%) had extrapulmonary tuberculosis, 
and 27 (13%) had both (table 2). The proportions of these 
diagnoses were comparable with the proportions of 
pulmonary tuberculosis and extrapulmonary tuberculosis 
in England as a whole.19 Patients with other diseases 
comprised a diverse group (table 2). 12 (2%) of the 
628 patients included in the final analysis were taking 
immunosuppressant medication at enrolment.
Transcriptomic analysis of 47 275 transcripts in whole 
blood showed 171 differentially expressed transcripts 
between patients with active tuberculosis and those with 





Culture-negative tuberculosis 76 (25%) ··
Smear-positive tuberculosis 50 (17%) ··
Smear-negative tuberculosis 198 (66%) ··
Smear not tested 53 (18%) ··
Pulmonary tuberculosis† 101 (34%) ··
Extrapulmonary tuberculosis 164 (54%) ··
Pulmonary tuberculosis plus 
extrapulmonary tuberculosis
36 (12%) ··
Site of tuberculosis infection‡
Abdomen 8 (3%) ··
Bone 6 (2%) ··
CNS 5 (2%) ··
Chest 2 (<1%) ··
Lung 136 (45%) ··
Lymph node 131 (44%) ··
Miliary tuberculosis (disseminated) 11 (4%) ··
Pericardium 5 (2%) ··
Pleura 23 (8%) ··
Spine 16 (5%) ··
Other site 22 (7%) ··
Pneumonia ·· 69 (21%)
Sarcoidosis ·· 34 (10%)
Cancer ·· 26 (8%)
Non-pneumonia lower respiratory 
tract infection
·· 24 (7%)
Bronchiectasis ·· 21 (6%)
Reactive lymphadenopathy ·· 14 (4%)
Upper respiratory tract infection ·· 10 (3%)
Asthma ·· 10 (3%)
Atypical Mycobacterium spp infection ·· 9 (3%)
Other diagnoses§ ·· 110 (34%)
*Some patients had multiple diagnoses. †For patients with highly probable 
tuberculosis, 16 (18%) had pulmonary tuberculosis, 64 (72%) had extrapulmonary 
tuberculosis, and nine (10%) had both. ‡Some patients had tuberculosis at 
multiple anatomical sites. §Fewer than five cases per diagnosis.
Table 2: Final presenting diagnoses of patients with tuberculosis and 
other diseases
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were derived in a randomly selected 80% and tested in a 
distinct 20% of the full (n=628) cohort for all patients 
with active tuberculosis (regardless of tuberculosis 
subgroup). The performance of these signatures was 
then tested in the different subgroups of tuberculosis 
(figure 2; table 3). The best-performing diagnostic 
signature derived from the whole cohort was signature 1, 
comprising 13 transcripts, with an AUC-ROC of 0·87 
(95% CI 0·81–0·92), sensitivity of 77% (66–87), and 
specificity of 84% (74–91) for identification of 
active tuberculosis. In patients with culture-confirmed 
pulmonary tuberculosis, it had an AUC-ROC of 0·88 
(0·77–0·96), sensitivity of 82% (65–95), and specificity 
of 83% (68–92), and in those with highly probable 
tuberculosis, these values were 0·86 (0·71–0·95), 
77% (56–94), and 77% (57–95; figure 2; table 3).
Diagnostic performance of signatures 1–3 was also 
assessed in patients with extrapulmonary tuberculosis 
(figure 2; table 3). Signature 1 performed best, with an 
AUC-ROC of 0·86 (95% CI 0·78–0·94), sensitivity of 
76% (61–91), and specificity of 82% (68–94).
For signatures derived exclusively in the highly 
probable tuberculosis subgroup, signature 4, comprising 
one transcript (GBP5), performed best and provided an 
AUC-ROC of 0·82 (95% CI 0·68–0·94), sensitivity of 
65% (42–87), and specificity of 84% (68–100). Signature 5 
had an AUC-ROC of 0·82 (0·68–0·94) and signature 6 
an AUC-ROC of 0·74 (0·59–0·90; appendix p 14).
The best-performing previously published signature 
for detecting active tuberculosis, culture-positive 
pulmonary tuberculosis, highly probable tuberculosis, 
and extra pulmonary tuberculosis was derived by Sweeney 
and colleagues.8 For detection of active tuberculosis, it 
had an AUC-ROC of 0·83 (95% CI 0·80–0·86), sensitivity 
of 78% (73–83), and specificity of 76% (70–80; table 3). 
For detecting highly probable tuberculosis, it had results 
of 0·71 (0·64–0·79), 76% (66–85), and 62% (51–72; 
table 3).
None of the relevant cohort-derived signatures or 
previously published signatures achieved minimal 
targets of paired sensitivity (98% for smear-positive 
culture-positive pulmonary tuberculosis and 65% for 
smear-negative culture-positive pulmonary and extra-
pulmonary tuberculosis) and specificity (98%) set by the 
WHO target product profiles for a non-sputum-based 
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Figure 2: Performance of the cohort-derived signatures in the whole cohort 
and tuberculosis subgroups
(A) Active tuberculosis (n=301) versus other diseases (n=327). (B) Culture-
confirmed pulmonary tuberculosis (n=112) versus other diseases (n=112). (C) 
Highly probable tuberculosis (n=89) versus other diseases (n=89) using signatures 
1–3, which were derived from the full all active tuberculosis cohort. (D) Highly 
probable tuberculosis (n=89) versus other diseases (n=89) using signatures 4–6, 
derived from the highly probable tuberculosis subgroup. (E) Extrapulmonary 
tuberculosis (n=164) versus other diseases (n=164). Error bars represent the 
95% CI. AUC-ROC=area under the receiver-operating characteristic curve.
Articles








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8 www.thelancet.com/infection   Published online January 25, 2021   https://doi.org/10.1016/S1473-3099(20)30928-2
novel signatures against them are reported in the 
appendix (pp 8, 15).
When the highly probable tuberculosis group was 
assigned true prevalence of 90%, the sensitivity of 
signature 1 increased to 77% (95% CI 47–100), at a 
prevalence of 85% it was 80% (47–100), and at a 
prevalence of 80% it was 84% (47–100; appendix p 14).
Discussion
In this large, multicentre, prospective cohort study in 
routine practice in a low-incidence setting that covered the 
full clinical spectrum of active tuberculosis and its 
differential diagnoses with concomitant latent tuberculosis 
infection, transcriptomic signatures showed suboptimal 
diagnostic accuracy, bringing their clinical utility into 
question. The best-performing cohort-derived signature 
for all tuberculosis cases and the best previously published 
signature for all tuberculosis categories8 had insufficient 
diagnostic accuracies, sensitivities, and specificities.
Signatures derived from our clinically relevant real-
life cohort by multiple methods and in key clinical 
tuberculosis subgroups performed only marginally 
better than pre-existing signatures, with none achieving 
an AUC-ROC of 0·90 in any clinical category, suggesting 
that a ceiling has been reached in the diagnostic 
potential of transcriptomic signatures in this setting. No 
signatures improved on the performance of IGRAs, 
with T-SPOT.TB achieving a sensitivity of 81% and 
specificity of 85% for active tuberculosis in this cohort.16 
Given that IGRAs are not recommended for the 
diagnosis of active tuberculosis because of insufficient 
diagnostic accuracy,16,20 it follows that transcriptomic 
signatures also cannot be recommended.
Two of the most promising previously published 
signatures were derived in case-control studies 
comparing culture-positive tuberculosis and other 
diseases.7,8 This could explain their reduced accuracy in 
our cohort and their poorer performance in identifying 
highly probable tuberculosis relative to culture-positive 
pulmonary tuberculosis. Another previously published 
signature was derived and validated by Anderson and 
colleagues6 in a large group of children with suspected 
tuberculosis (discovery cohort n=346, validation cohort 
n=157) in high-incidence, low-resource settings. This 
signature achieved an AUC-ROC of 0·89 (95% CI 
0·82–0·95), sensitivity of 83% (67–94), and specificity 
of 83% (73–92). Its reduced performance in our cohort 
probably reflects differences in the study populations; 
children might have a distinct transcriptomic response to 
tuberculosis. Additionally, the differential diagnoses of 
non-tuberculosis cases in their child cohort differ greatly 
from adults; there were no cases of cancer or sarcoidosis 
in these children, whereas malnutrition, malaria, and 
helminth infections were frequent. To address the 
question of whether other sig natures might perform 
better, the transcriptomic data from our cohort will be 
publicly available to enable future investigators to assess 
the performance of other published or novel signatures 
in our cohort. Culture-unconfirmed, highly probable 
tuberculosis and extrapulmonary tubercu losis have 
unmet diagnostic needs, for which hope has been pinned 
on non-sputum-based host-response biomarkers, 
particularly transcriptomics. Our study provides the first 
assessment of this technology in these key subgroups of 
adults with tuberculosis. The two previously published 
signatures derived exclusively from culture-confirmed 
pulmonary tuberculosis performed markedly less well in 
diagnosing highly probable tubercu losis. The novel 
signatures showed inferior performance for identification 
of highly probable tuberculosis than for culture-
confirmed tuberculosis, even when we derived signatures 
specifically from and for that subgroup.
A strength of our study is the rigorous case definition 
for highly probable tuberculosis that used a validated 
composite reference standard, including appropriate 
response to therapy after 6 months.16,17 The need to 
define a composite reference standard demonstrates the 
diagnostic challenge of culture-negative tuberculosis in 
this setting and hence the need for a rapid, accurate test. 
Moreover, clinically indeterminate patients, in whom 
tuberculosis could not be ruled out but who did not 
meet the composite reference standard for highly 
probable tuberculosis, comprised only a small 
fraction (5%) of the cohort and were excluded from 
analysis as planned. However, a proportion of patients 
with highly probable tuberculosis could conceivably 
have been misclassified, which might falsely lower the 
accuracy of the signatures. We tested this hypothesis 
with a sensitivity analysis, in which the prevalence of 
tuberculosis cases in the highly probable tuberculosis 
group was set to 80%, 85%, and 90%. The results 
showed that even when 20% of the patients were 
assumed to be misclassified by our composite reference 
standard, improvement in the signature’s performance 
was inadequate.
In our cohort, no novel or previously published 
signatures achieved the minimal WHO sensitivity (65%) 
and specificity (98%) cutoffs for a non-sputum-based 
confirmatory test for sputum smear-negative tuberculosis, 
using culture-confirmed tuberculosis as a gold standard. 
This finding aligns with studies21,22 of previously published 
signatures in cohorts of 181 and 293 patients with 
suspected pulmonary tuberculosis in very-high-incidence 
settings, which showed that the signatures did not meet 
these WHO requirements.
Thus, we found that in a routine practice setting where 
tuberculosis must be differentiated from other diseases 
with similar clinical presentations, transcriptomic 
signatures did not show sufficient diagnostic accuracy 
to be clinically useful. This finding might be because 
a positive transcriptomic signature is a marker of inflam-
mation in response to a foreign stimulus, rather than a 
marker of the specific pathogen, making its diagnostic 
specificity inadequate to deliver a positive result reliable 
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enough to initiate tuberculosis therapy. Diagnosis of an 
infectious disease using antigen or immune response 
to antigen, however, relies on pathogen specificity. 
Future work on transcriptomic signatures should 
perhaps therefore combine them with antigen-stimulated 
responses.
This study had some limitations. Our findings cannot 
be extrapolated to children or to high-incidence, low-
resource settings, although two smaller studies21,22 of 
patients with suspected pulmonary tuberculosis in 
South Africa have also suggested insufficient diagnostic 
accuracy. Additionally, owing to the low prevalence of 
HIV-associated tuberculosis in our cohort (20 [7%] of 
301 patients), conclusions cannot be drawn about the use 
of transcrip tomics in this co-infected group, although 
there is no reason to believe performance would be better 
in the presence of HIV co-infection. To reduce the dispro-
portionately large number of HIV-positive patients with 
other diseases, a subgroup of these patients were selected 
randomly. A similar method was used by Anderson and 
colleagues6 and would not be expected to alter the validity 
of the overall results. Although RNA sequencing is 
superseding the use of microarrays, a microarray was 
used here to enable parallel assessment of previously 
published signatures, all of which were developed with 
microarrays. Because RNA sequencing also quantifies 
abundance of transcripts, unstimulated whole-blood 
RNA sequencing would probably not perform sub-
stantially better. The small proportion of participants 
taking immuno suppressant medication, 2% of the final 
cohort, is unlikely to have affected our analysis. The 
distribution of ethnicity in our cohort is representative of 
patients with suspected tuberculosis in routine clinical 
practice in England.19
In summary, these strong, generalisable data do not 
support the use of transcriptomic signatures as 
diagnostic tools for tuberculosis in routine practice in 
low-incidence, high-resource settings.
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